CRESCENT BIOPHARMA, INC. (CBIO) Form 424B5 — Jul 15, 2026
Crescent Biopharma is pricing a public offering of 8.1 million ordinary shares and pre-funded warrants to purchase approximately 525,897 additional shares at a public offering price of $14.50 per share. The gross proceeds are expected to be approximately $125 million, with an option for underwriters to purchase an additional 1.3 million shares. The company intends to use the net proceeds to fund clinical development of its oncology candidates, including CR-001, CR-002, and CR-003, alongside working capital and general corporate purposes. Combined with existing cash of approximately $171.6 million, the company estimates the funds will support operations into the second half of 2028.
Key figures
- Cash Position
- 171600000
- Gross Proceeds
- 124999479
- Offering Price
- 14.5
- Shares Offered
- 8,094,793 shares and 525,897 pre-funded warrants
- Greenshoe
- 1293103
- Dilution Per Share
- 6.1
- Warrant Exercise Price
- 0.001
Price after filing
Close on the filing date to close N calendar days later (from $15.67). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.